Navigation Links
Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
Date:9/23/2010

t to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.  

ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD).  

Under terms of the agreement, Reata will grant to Abbott exclusive rights to develop and commercialize bardoxolone outside the U.S., excluding certain Asian markets.  Reata will receive upfront and near-term cash payments of $450 million for the licensing rights to bardoxolone and a minority equity investment in the company.  Upon completion of certain development and approval objectives for bardoxolone and other molecules in the licensed territories, Reata will receive additional milestone payments.  Reata also will receive royalties on any future product sales in the Abbott territories.  Additionally, Abbott obtains rights to develop and commercialize certain other Reata compounds for chronic kidney disease, and for cardiovascular and metabolic indications, in these territories.

"Early clinical studies suggest that bardoxolone could be a significant improvement to the current standard of care for CKD and possibly prevent patients from progressing to the later stages of the disease and dialysis," said John Leonard, M.D., senior vice president, pharmaceuticals, research and development, Abbott.  "This agreement builds on Abbott's existing experience in renal care, while adding a promising compound to our later-stage pipeline."

Bardoxolone is an oral, first-in-class antioxidant inflammation modulator that works by increasing the estimated glomerular filtration rate (eGFR) of the kidneys.
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... -- The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic ... & by Region ( North America , ... Rest of the World) - Global Trends and Forecast to ... valued at USD 4.62 Billion in 2014 and is projected ... of 7.4% from 2015 to 2020. Browse ...
(Date:8/27/2015)... , Aug. 27, 2015  The Academy of ... and Drug Administration,s (FDA,s) draft guidance and proposed ... and biosimilars, to bear a nonproprietary name with ... been seeking a decision from the FDA on ... health care stakeholders urging the agency to use ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
(Date:8/28/2015)... ... 29, 2015 , ... Rio Salado College joined nine educational institutions ... part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded ... Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed to ...
(Date:8/28/2015)... ... 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth ... are applying for, they are unable to pass the initial drug test and therefore ... policies in order to be able to hire long-term, skilled talent. (1) Will Wesch, ...
(Date:8/28/2015)... Falls Church, VA (PRWEB) , ... ... ... and Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and ... – Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... who might personally be struggling with chemical dependency, may be able to find ... Rehabilitation, a results-driven holistic treatment center for addiction located in Western Michigan. Focusing ...
(Date:8/28/2015)... ... August 28, 2015 , ... Drugs and alcohol ... Strawbridge, gives a new approach on solutions in his new book ":Unraveling The ... and employees getting together for meaningful group meetings. "This would educate the employees ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... Data Can Be Integrated with Other Sales & ... Key Performance Indicators, Dynamic Graphs, And Custom Metrics ... leader in pharmaceutical data analysis and reporting solutions, ... within InView, the company,s graphical interactive portal for ...
... April 29 New analyses of data from ... beta-1b), sponsored by Bayer HealthCare Pharmaceuticals, were presented ... Annual Meeting. The study results showed that ... participants with multiple sclerosis (MS) were more likely ...
... warns more deaths are likely , , WEDNESDAY, April 29 ... become the first U.S. fatality in the spreading swine ... Dr. Richard Besser, acting director of the U.S. Centers ... other details on the case were immediately available, according ...
... Diluted Earnings per Share were $0.89, , Consistent ... Excluding Certain Significant Items, Increased 1% to $0.95- Worldwide ... , Increased 2%, Excluding the Impact of Foreign Exchange ... , Exchange, was Driven by Increases of 23% ...
... vs. $25.2 million - Increase of 34%Record Quarterly Diluted EPS: $0.17 vs. ... OWINGS MILLS, Md., April 29 Medifast, Inc. (NYSE: MED ... 31, 2009. First Quarter highlights included: , , ... quarter revenues increased 34% compared to 2008 to $33.7 million; , ...
... consider healthy hearing for spring 2009 , ... Stäfa, ... spring marks an opportunity for Americans to refresh and revitalize themselves. ... global initiative to inform and educate the public about the importance ...
Cached Medicine News:Health News:Archi-Tech InView Now Supports Managed Care Data, Offering an Interactive Dashboard for On-Demand Sales Planning and Reporting 2Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 2Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 3Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 4Health News:U.S. Reports First Swine Flu Death 2Health News:U.S. Reports First Swine Flu Death 3Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 2Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 3Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 4Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 5Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 6Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 7Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 8Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 9Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 10Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 11Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 12Health News:Medifast Reports Record First Quarter 2009 Financial Results 2Health News:Medifast Reports Record First Quarter 2009 Financial Results 3Health News:Medifast Reports Record First Quarter 2009 Financial Results 4Health News:Medifast Reports Record First Quarter 2009 Financial Results 5Health News:Medifast Reports Record First Quarter 2009 Financial Results 6Health News:Medifast Reports Record First Quarter 2009 Financial Results 7Health News:Medifast Reports Record First Quarter 2009 Financial Results 8Health News:Medifast Reports Record First Quarter 2009 Financial Results 9Health News:This Spring, Hear the World 2Health News:This Spring, Hear the World 3
... workstations is designed for laboratories with limited ... automation platform for routine sample preparation and ... throughput, process consistency and safety. Windows ... you to control the robotic and liquid ...
... The Labcyte miniGene LD is a ... to 96-, 384- and 1536-well microplates. This ... 16 channel standard or wide orifice nozzle ... movement allow for accurate dispensing to a ...
... The QFill2 is the ideal system for fast, ... The pressure driven, pinch valve controlled dispensing mechanism, ... Whilst all of the components that come into ... dismantle, clean, and autoclave. The unique compact design ...
... an innovative reagent dispenser for plate ... fulfill the need for precise automated ... more, FlexDrop provides an efficient solution ... tedious task of plate preparation for ...
Medicine Products: